Production (Stage)
Algernon Pharmaceuticals Inc.
AGN
CNSX
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.10% | 9.98% | -129.04% | 241.81% | -95.60% |
| Total Depreciation and Amortization | 5.00% | 2.56% | -13.33% | -21.05% | 5.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 66.42% | 294.12% | 100.25% | -1,315.38% | 91.11% |
| Change in Net Operating Assets | -27.86% | 150.93% | 84.11% | -336.01% | 53.82% |
| Cash from Operations | 1.75% | 61.59% | 64.75% | -557.55% | -420.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.17% | 40,209.52% | -- |
| Cash from Investing | -- | -- | -100.17% | 40,209.52% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -99.94% | 4,454.67% | -97.18% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -99.96% | 8,238.18% | -97.22% | -- |
| Foreign Exchange rate Adjustments | -120.00% | 214.29% | -206.06% | 430.00% | -200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -7.22% | -1,685.57% | -102.48% | 24,356.25% | 104.29% |